Researchers at Pennington Biomedical are conducting a study to test the effects of a study drug in patients with Non-alcholic steatohepatitis, a condition that results in liver damage due to a build-up of fat in the liver. While common, most people with NASH feel well and are not aware that they have a liver problem.
However, NASH can lead to severe cirrhosis, condition that can cause permanent liver damage and scarring.
To qualify for this research study, participants should:
Be 18 years of age or older
Have been diagnosed by their doctor with either: NASH, Obesity or Type 2 diabetes mellitus.
Other study qualifications will be assessed during the screening process.
Participation in this research study will last approximately 4 to 6 months.
Compensation of up to $1,700 is offered for completion of the study.
Copyright 2017 WAFB. All rights reserved.